Trial 0C-23-21


PhII-227 / NCI 10486: Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Biological Response Modifier, Immunotherapy
Randomized: No
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Mary Ordaz, D.M., Kristy Sartor Massopust, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Negeen Izadian, Coordinator, Nazeli Livaskani, Coordinator, Bomi Choi, Coordinator, Brianna Olea, Coordinator, Marc Cruz, D.M., Stephanie Kim, Coordinator, Maura Fernandez, D.M., Teshia Bustos, Coordinator, Alexandra Artura, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.